Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline

International Clinical Psychopharmacology

Volumn 3, Issue 1, 1988, Pages 59-74

  Den Boer, Johan A ^a   Westenberg, Herman G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ANTHRACENE DERIVATIVE; FLUVOXAMINE; MAPROTILINE; OXIME; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ADULT; AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; BRAIN; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEAR; FEMALE; HUMAN; MALE; PANIC; PHOBIA; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGORAPHOBIA; ANTHRACENES; ANXIETY DISORDERS; BRAIN; CLINICAL TRIALS; COMPARATIVE STUDY; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEAR; FEMALE; FLUVOXAMINE; HUMAN; MALE; MAPROTILINE; OXIMES; PANIC; PHOBIC DISORDERS; PSYCHOLOGICAL TESTS; RECEPTORS, ADRENERGIC; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0023672570     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/00004850-198801000-00005     Document Type: Article

References (62)

1. Cedarbaum, J. M. and Aghajanian, G. K. (1976). Noradrenergic neurons of the locus coeruleus: Inhibition by epinephrine and activation by the alpha-antagonist piperox- anc. Brain Research, 112, 413-419.
2. Cedarbaum, J. M. and Aghajanian, G. K. (1977). Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. European Journal of Pharmacology, 44, 375-385.
3. Cculemans, D. L. S., Hoppenbrouwers, M. -L. J. A., Gcldcrs, Y. G., and Rcyntjens, A. J. M. (1985). The influence of ritanscrin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled studv versus lorazepam. Pharmacopsychiatry, 18. 303-305.
4. Charney, D. S., Heninger, G. R., Reinhard, J. F., Sternberg, O., Hafstad, K. (1982) The effect of intravenous L-tryptophan on prolactin and growth hormone and mood in healthy subjects. Psychopharmacology, 78, 217-22.
5. Charney, D. S. and Heninger, G. R. (1985a). Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment. Archives of General Psychiatry, 42, 458-467.
6. Charney, D. S. and Heninger, G. R. (1985b). Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment. Archives of General Psychiatry, 42, 473-481
7. Charney, D. S., and Heninger, G. R. (1986a). Abnormal regulation of noradrenergic function in panic disorders. Archives of General Psychiatry. 43, 1042-1054.
8. Charney, D. S. and Heninger, G. R. (1986b). Serotonin function in panic disorders. The effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment. Archives of General Psychiatry, 43, 1059-1065.
9. Charney, D. S., Menkes, D. B. and Heninger, G. R. (1981). Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and therapy of depression. Archives of General Psychiatry, 38, 1160-1180.
10. Charney, D. S., Heninger, G. R. and Redmond, D. E. (1983). Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sciences, 33, 19-29.
11. Charney, D. S., Heninger, G. R., and Breier, A. (1984). Noradrenergic function in panic anxiety. Effects of Yohimbine in health subjects and patients with agoraphobia and panic disorder. Archives of General Psychiatry. 41, 751-763.
12. Charney, D. S., Woods, S. W., Goodman, W. K., Rifkin, B., Kinch, M., Aiken, B., Quadrino, L. M. and Heninger, G. R. (1986). Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. Journal of Clinical Psychiatry, 47, 580-586.
13. Claasen, V. (1983). Review of the animal pharmacology and pharmacokinetics of fluvoxamine. British Journal of Clinical Pharmacology, 15 (S3), 349S-355S.
14. Den Boer, J. A., Westenberg, H. G. M., Kamerbeek, W. D. J., Verhoeven, W. M. A., and Kahn, R. S. (1987). The effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. International Clinical Psychopharmacology. 2. 21-32.
15. Derogatis, L. R., Lipman, R. S., and Covi, L. (1973). SCL-90: An outpatient psychiatric rating scale: Preliminary report. Psychopharmacology Bulletin, 9, 13-28.
16. Dijkstra, P. (1974). De Zelfbcoordelingsschaal voor de depressie van Zung. In "Stemming en Ontstemming” (Eds. H. M. Van Praag and H. G. M. Rooymans). pp. 98-121, De Erven Bohn, Amsterdam.
17. Dominguez, R. A., Goldstein, D. J., Jacobson, A. F. and Steinbook, R. M. (1985). A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. Journal of Clinical Psychiatry. 46, 84-87.
18. DSM-III. (1980). Diagnostic and Statistical Manual of Mental Disorder. The American Psychiatric Association.
19. Evans, L. and Moore, G. (1981). The treatment of phobic anxiety by zimelidine. Acta Psyehiatrica Scandinavica, 63 (S290), 342-345.
20. Evans, L., Kenardy, J., Schneider, P. and Hoey, H. (1986). Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine. imipramine and placebo, Acta Psychiatrica Scandinavica, 73, 49-53.
21. Feuerstein, T. J., Hertting, G., and Jackisch R. (1985). Endogenous noradrenaline as modulator of hippocampal serotonin (5-HT)-release. Naunyn-Schmiedeherg's Archiv für Pharmacologie. 329, 216-221.
22. File, S. E. (1978). Anxiety, ACTH and 5-HT. Trends in Neurosciences. 9-11.
23. File, S. E. (1980). The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. Journal of Neuroscience Methods, 2. 219-238.
24. File, S. F. (1984). The neurochemistry of anxiety. In "Anti-Anxiety Agents" (Eds. G. D. Rurrown, T. R. Norman and B. Davies), pp. 13-34, Elsevier Science Publishers, Amsterdam.
25. File, S. F., Deakin, J. F. W., Longden, A. and Crow, T. J. (1979). An investigation of the role of the locus coeruleus in anxiety and agonistic behaviour. Brian Research, 169, 411-420.
26. Garvey, M. J., Tollefson, G. D., and Orsulak, P. J. (1987). Elevations of urinary MI IPG in depressed patients with panic attacks. Psychiatry Research, 20, 183-187.
27. Gray, J. A. (1985). Issues in the Neuropsychology of Anxiety, in "Anxiety and the Anxiety Disorders" (Eds. A. H. Tuma. J. D. Maser), pp. 5-26, Lawrence Erlbaum and Associates. Hillsdale. New Jersey. London.
28. Gray, J. A., Holt, L., McNaughton, N. (1983). Clinical implications of the experimental pharmacology of the benzodiazepines. In “The Benzodiazepines; From Molecular Biology to Clinical Practice” (Ed. H. Costa), pp. 147-171, Raven Press, New York.
29. Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50-55.
30. Hamilton, M. (1960). A Rating Scale for Depression. Journal of Neurology, Neurosurgery and Psychiatry, 23. 56-62.
31. Hamilton, M. (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278-296.
32. Hoehn-Saric, R., Merchant, A. F., Keyser, M. I., and Smith, V. K. (1981). Effects of clonidine on anxiety disorders. Archives of General Psychiatry, 38. 1278-1282.
33. Kahn, R. J., McNair, D. M., Lipman, R. S., Covi, I., Riekels, K., Downing, R., Fisher, S., and Frankenthaler, L. M. (1986). Imipramine and chlordiazepoxide in depressive and anxiety disorders. 11. Efficacy in anxious outpatients. Archives of General Psychiatry, 43, 79-85.
34. Kahn, R. S., Westenberg, H. G. M., Verhoeven, W. M. A., Gispen-dc Wicd, C. C., and Kamcrbcek, W. D. J. (1987). Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan. clomipramine and placebo. International Clinical Psychopharmacology, 2, 33-45.
35. Klein, D. F. (1964). Delineation of two drug-rcsponse anxiety syndromes. Psychopharmacologica, 5, 397-408.
36. Klein, D. F. (1980). Anxiety reconceptualized. Comprehensive Psychiatry, 21, 411-427.
37. Klein, D. F., Zirin, C. M. and Woerner, M. G. (1978). Antidepressants, anxiety, panic, and phobia. In “Psychopharmacology: A Generation of Progress” (Eds. M. A. Lipton, A. DiMascio and K. F. Killam). pp. 1401-1410, Raven Press, New York.
38. Klein, D. F., Rabkin, J. G. and Gorman, J. M. (1985). Etiological and pathophysiological inferences from the pharmacological treatment of anxiety. In “Anxiety and the Anxiety Disorders” (Eds. A. H. Tuma, J. D. Maser), pp. 501-532, Lawrence Erlbaum and Associates, Hillsdale. New Jersey, London.
39. Klok, C. J., Brouwer, G. J., Van Praag, H. M., and Doogan, D. (1981). Fluvoxamine and clomipramine in depressed patients: a double-blind clinical study. Acta Psychiatrica Scandinavica, 64, 1-11.
40. Ko, G. N., Elsworth, J. D., Roth, R. H., Rifkin, B. G., Leigh, H., and Redmond, D. E. (1983). Panic-induced elevation of plasma MHPG in phobic anxious patients: Effects of clonidine or imipramine. Archives of General Psychiatry. 40, 425-430.
41. Kockzkas, S., Holmberg, G., and Wedin, L. (1981). A pilot study of the effect of 5-HT uptake inhibitor, zimeldine, on phobic anxiety. Acta Psychiatrica Scandinavica, 63 (S290), 328-341.
42. Liebowitz, M. R., Fyer, A. J., and McGrath, P. (1981). Clonidine treatment of panic disorder. Psychopharmacology Bulletin, 17, 122-123.
43. Maître, L., Waldmeier, P. C., Greengrass, P. M., Jaekel, J., Sedlacek, S. and Delini-Slula, A. (1975). Maprotiline its position as an anti-depressant in the light of recent ncurophar-macological and neurobiochemical findings. The Journal of International Medical Research, 3. 2-15.
44. Mavissakalina, M. (1983). Antidepressants in the treatment of agoraphobia and obsessive-compulsive disorder. Comprehensive Psychiatry, 24, 278-284.
45. Redmond, D. F., and Huang, Y. H. (1979). New evidence for a locus coeruleus-norepinephrine connection with anxiety. Life Sciences, 24, 2149-2162.
46. Richelson, E., and Nelson, A. (1984). Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. Journal of Pharmacology and experimental Therapeutics. 230, 94-102.
47. Sheehan, D. V., Bao, Bch., Ballenger, J., and Jacobsen, G. (1980). Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Archives of General Psychiatry, 37, 51-59.
48. Spielberger, C. D. (1980). Test manual for the Slate-Trait Anxiety Inventory -STA1 from Y. Consulting Psychologists Press. Palo Alto, California.
49. Spitzer, R. L., and Williams, J. B. W. (1985). Proposed revisions in the DSM-III classification of anxiety disorders based on research and clinical experience. In “Anxiety and Anxiety Disorders” (Eds. A. H. Tuma and J. D. Maser), pp. 759-774. Lawrence Erlbaum and Associates, Hillsdale, New Jersey, London.
50. Sweeney, D. R., Maas, J. W. and Heninger, G. R. (1978). State anxiety, physical activity and urinary 3-methoxy-4-hydroxy-phenthylcne glycol excretion. Archives of General Psychiatry, 35, 1418-1423.
51. Tenen, S. S. (1967). The effects of p-chlorophenylalanine. a serotonin depletor, on avoidance acquisition, pain sensitivity and related behaviour in the rat. Psychopharmacologia, 10, 204-219.
52. Van Praag, H. M. (1983). In search of the mode of action of antidepressants: 5-HTP tyrosine mixtures in depression. Neuropharmacology, 22, 433-440.
53. Van Praag, H. M., Lemus, C., and Kahn, R. (1987). Hormonal probes of central serotonergic activity: Do they really exist"? Biological Psychiatry, 22, 86-98.
54. Van der Ploeg, H. M., Defares, P. B., and Spielberger, C. D. (1981). “Handleiding bij de zelf- beoordeingsvragenlijst”. Ed. by Swets and Zeitlinger B. V., Lisse.
55. Westenberg, H. G. M., Gerritsen, T. W., Meijer, B. A., and Van Praag, H. M. (1982). Kinetics of L-5-hydroxytryptophan in healthy subjects. Psychiatry Research, 1, 373-383.
56. Willner, P. (1985). Antidepressants and serotonergic neurotransmission: an integrative review. Psychopharmacology, 85, 387-404.
57. Wing, J. K., Cooper, J. E. and Sartorius, N. (1975). “The Measurement and Classification of Psychiatric Symptoms". Cambridge University Press.
58. Wise, C. D., Berger, B. D. and Stem, L. (1972). Benzodiazepines-Anxiety-reducing activity by reduction of serotonin turnover in the brain. Science, 177. 180-183.
59. Zitrin, C. M., Klein, D. F., and Woerner, M. G. (1978). Behaviour therapy, supportive psychotherapy, imipramine. and phobias. Archives of General Psychiatry. 35, 307-316.
60. Zitrin, C. M., Klein, D. F., and Woerner, M. G. (1980). Treatment of agoraphobia with group exposure in vivo and imipramine. Archives of General Psychiatry, 37, 63-72.
61. Zitrin, C. M., Klein, D. F., Woerner, M. G. and Ross, D. C. (1983). Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Archives of Genera! Psychiatry, 40, 125-138.
62. Zung, W. W. K. (1965). A self-rating depression scale. Archives of General Psychiatry, 12, 63-70.